These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 36479136

  • 21. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L, Chen L, Lv S, Li Q, Chen G, Luo W, Zhou P, Li G.
    Radiat Oncol; 2019 Jun 13; 14(1):104. PubMed ID: 31196126
    [Abstract] [Full Text] [Related]

  • 22. The efficacy and safety of low-dose temozolomide maintenance therapy in elderly patients with glioblastoma: a retrospective cohort study.
    Tao Q, Zhu T, Ge X, Gong S, Guo J.
    Ann Palliat Med; 2022 Nov 13; 11(11):3513-3519. PubMed ID: 36464967
    [Abstract] [Full Text] [Related]

  • 23. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
    Shawky H, Abo Hamar AH, Galal S, Zakaria F, El-Shorbagy D.
    J Egypt Natl Canc Inst; 2009 Jun 13; 21(2):107-19. PubMed ID: 21057562
    [Abstract] [Full Text] [Related]

  • 24. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.
    J Neurosurg; 2014 Sep 13; 121(3):543-53. PubMed ID: 24995786
    [Abstract] [Full Text] [Related]

  • 25. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide.
    Topkan E, Besen AA, Mertsoylu H, Kucuk A, Pehlivan B, Selek U.
    Int J Inflam; 2020 Sep 13; 2020():6947382. PubMed ID: 32566124
    [Abstract] [Full Text] [Related]

  • 26. Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy.
    Chen Y, Gong L, Gu P, Hua Y, Sun Y, Ni S, Zhou X, Tang Z.
    BMC Cancer; 2023 Oct 06; 23(1):944. PubMed ID: 37803437
    [Abstract] [Full Text] [Related]

  • 27. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR.
    J Neurooncol; 2012 Apr 06; 107(2):395-405. PubMed ID: 22105851
    [Abstract] [Full Text] [Related]

  • 28. Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study.
    Chen J, Wang T, Liu W, Qiu H, Zhang N, Chen X, Ding X, Zhang L.
    Front Oncol; 2022 Apr 06; 12():1000501. PubMed ID: 36483042
    [Abstract] [Full Text] [Related]

  • 29. Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.
    Singh R, Lehrer EJ, Wang M, Perlow HK, Zaorsky NG, Trifiletti DM, Bovi J, Navarria P, Scoccianti S, Gondi V, Brown PD, Palmer JD.
    Int J Radiat Oncol Biol Phys; 2021 Oct 01; 111(2):371-384. PubMed ID: 33991621
    [Abstract] [Full Text] [Related]

  • 30. Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
    Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G.
    Oncologist; 2017 May 01; 22(5):570-575. PubMed ID: 28360216
    [Abstract] [Full Text] [Related]

  • 31. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
    Wang J, Huang Y, Zhao F, Chen J, He L, Liu Z, Pei Y, Wei Z, Li R, Ai P, Peng X.
    J Neurooncol; 2022 Nov 01; 160(2):433-443. PubMed ID: 36357822
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Optimizing Postoperative Adjuvant Therapy in Elderly Patients with Newly Diagnosed Glioblastoma: Single-Institution Audit of Clinical Outcomes from a Tertiary-Care Comprehensive Cancer Center in India.
    Chatterjee A, Bhadane M, Manjali JJ, Dasgupta A, Epari S, Sahay A, Patil V, Moiyadi A, Shetty P, Gupta T.
    World Neurosurg; 2022 May 01; 161():e587-e595. PubMed ID: 35192971
    [Abstract] [Full Text] [Related]

  • 37. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ, Nahed BV, Muzikansky A, Fathi AT, Dietrich J.
    J Neurosurg; 2017 Jul 01; 127(1):132-138. PubMed ID: 27739940
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.
    Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A.
    Int J Radiat Oncol Biol Phys; 2018 Apr 01; 100(5):1195-1203. PubMed ID: 29722661
    [Abstract] [Full Text] [Related]

  • 40. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
    Wang Y, Pan L, Sheng XF, Chen S, Dai JZ.
    Asia Pac J Clin Oncol; 2016 Mar 01; 12(1):e23-9. PubMed ID: 24571331
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.